ZAGNI, Irene
 Distribuzione geografica
Continente #
NA - Nord America 776
EU - Europa 538
AS - Asia 198
SA - Sud America 2
OC - Oceania 1
Totale 1515
Nazione #
US - Stati Uniti d'America 776
GB - Regno Unito 228
CN - Cina 193
SE - Svezia 78
FR - Francia 67
IE - Irlanda 59
DE - Germania 33
FI - Finlandia 25
IT - Italia 23
UA - Ucraina 15
RO - Romania 3
AT - Austria 2
IN - India 2
NL - Olanda 2
TR - Turchia 2
AU - Australia 1
BG - Bulgaria 1
BR - Brasile 1
CL - Cile 1
IR - Iran 1
PL - Polonia 1
RU - Federazione Russa 1
Totale 1515
Città #
Southend 197
Chandler 184
Jacksonville 182
Woodbridge 95
Houston 80
Dublin 59
Ann Arbor 49
Nanjing 30
Wilmington 29
Jinan 27
Lawrence 23
Princeton 23
Shenyang 23
Lancaster 20
Ashburn 19
Haikou 13
Hebei 13
Tianjin 12
Nanchang 9
Rome 9
Hangzhou 8
Beijing 7
Boardman 7
Changsha 6
Jiaxing 6
Ningbo 6
Taiyuan 6
Taizhou 6
Verona 6
Milan 5
Zhengzhou 5
Falls Church 4
Lanzhou 4
Guangzhou 3
Leawood 3
Nürnberg 3
Qingdao 3
San Mateo 3
Auburn Hills 2
Bangalore 2
Chicago 2
Edinburgh 2
Norwalk 2
San Diego 2
Timisoara 2
Ardabil 1
Augusta 1
Canberra 1
Fairfield 1
Monmouth Junction 1
Oklahoma City 1
Provo 1
Redwood City 1
San Francisco 1
Seattle 1
Sofia 1
São Paulo 1
Vienna 1
Warsaw 1
Totale 1215
Nome #
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 107
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 80
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 77
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 76
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 75
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 72
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 69
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 69
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 67
Natural course and prognostic factors of hepatitis B. 64
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 64
Natural history of hepatitis B and prognostic factors of disease progression 62
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 62
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 62
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 61
Hepatocellular carcinoma in cirrhosis:incidence and risk factors 60
Natural history of hepatitis B virus infection and disease 60
The risk of hepatocellular carcinoma (HCC) among patients with cirrhosis 60
Incidenza e fattori di rischio di epatocarcinoma. 59
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 58
Storia naturale della epatite cronica e cirrosi da virus C. 53
The risk of hepatocellular carcinoma (HCC) in cirrhosis 51
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 49
Totale 1517
Categoria #
all - tutte 2998
article - articoli 966
book - libri 0
conference - conferenze 1544
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 488
Totale 5996


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182 0000 00 00 0002
2018/201975 01244 62 260 3513
2019/2020204 332023 118 2423 726641
2020/2021214 14423515 1519 023 150333
2021/2022163 104313 265 210 113841
2022/2023441 33644092 3298 723 42370
Totale 1517